NDAORALCAPSULEPriority Review
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
MODEYSO (dordaviprone) by Chimerix is protease activators [moa]. Approved for protease activator [epc]. First approved in 2025.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODEYSO (dordaviprone) is an oral protease activator approved by FDA on August 6, 2025, representing a novel mechanism within its therapeutic class. The drug is delivered as a capsule and targets protease-dependent pathways. Patient population and specific clinical indications are designated by its protease activator classification.
Launch10.6 years to LOE
Early-stage launch product with zero current competitive pressure, offering significant opportunity for commercial teams to establish market position.
Mechanism of Action
Protease Activators
Pharmacologic Class:
Protease Activator
Indications (1)
Career Relevance
MODEYSO represents a launch-stage opportunity with significant career visibility and responsibility—establishing a new protease activator category with no competition requires strategic thinking and execution excellence. Teams joining now will build foundational market strategy and patient programs with potential for rapid advancement as the product scales.
Worked on MODEYSO at Chimerix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.